Sean E. Harper
Chief Executive Officer chez Amgen Rockville, Inc.
Postes actifs de Sean E. Harper
Sociétés | Poste | Début | Fin |
---|---|---|---|
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Director/Board Member | 02/03/2012 | - |
Chief Executive Officer | 02/03/2012 | - | |
President | 02/03/2012 | - | |
Westlake Biopartners LLC
Westlake Biopartners LLC Investment ManagersFinance Westlake Biopartners LLC (Westlake Biopartners) is a venture capital firm founded in 2018. The firm is headquartered in Westlake Village, California. | Private Equity Investor | 01/01/2019 | - |
Jamanda Ltd.
Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | Director/Board Member | - | - |
3T Biosciences, Inc.
3T Biosciences, Inc. BiotechnologyHealth Technology 3T Biosciences, Inc. operates as immunotherapy company. The company was founded by Luke J. Lee, Marvin Gee and Leah Sibener and is headquartered in Palo Alto, CA. | Chairman | 25/08/2022 | - |
Dantari, Inc.
Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | Chairman | - | - |
Historique de carrière de Sean E. Harper
Anciens postes connus de Sean E. Harper
Sociétés | Poste | Début | Fin |
---|---|---|---|
AMGEN INC. | Chief Tech/Sci/R&D Officer | 15/02/2012 | - |
Corporate Officer/Principal | 01/01/2002 | 26/07/2018 | |
ACELYRIN, INC. | Director/Board Member | - | - |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Director/Board Member | - | - |
President | - | - | |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Executive Officer | - | - |
░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formation de Sean E. Harper
University of California, Berkeley | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 11 |
Royaume-Uni | 2 |
Opérationnelle
Director/Board Member | 4 |
Corporate Officer/Principal | 2 |
Chief Executive Officer | 2 |
Sectorielle
Health Technology | 9 |
Finance | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
AMGEN INC. | Health Technology |
ACELYRIN, INC. | Health Technology |
Entreprise privées | 8 |
---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Health Technology |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Health Technology |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
3T Biosciences, Inc.
3T Biosciences, Inc. BiotechnologyHealth Technology 3T Biosciences, Inc. operates as immunotherapy company. The company was founded by Luke J. Lee, Marvin Gee and Leah Sibener and is headquartered in Palo Alto, CA. | Health Technology |
Westlake Biopartners LLC
Westlake Biopartners LLC Investment ManagersFinance Westlake Biopartners LLC (Westlake Biopartners) is a venture capital firm founded in 2018. The firm is headquartered in Westlake Village, California. | Finance |
Jamanda Ltd.
Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | Finance |
Dantari, Inc.
Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | Health Technology |
- Bourse
- Insiders
- Sean E. Harper
- Expérience